Loading stock data…
GMAB
$26.55-0.54 (-1.99%)
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Genmab A/S in the Healthcare sector is trading at $26.55. Wall Street consensus targets $37.55 (11 analysts), implying a +41.4% move over the next 12 months. The stock is currently 25% below its 52-week high of $35.43, remaining 8.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +41.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$26.55
Potential Upside
38.2%
Whystock Fair Value$36.68
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$37.55+41.4%
Range$32.00 – $48.00
Fundamentals
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diff...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$16.60B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
17.56
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
21.04%
Volume
Today's trading volume
1.98M
Recent News
Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 8, Morgan Stanley reduced its price goal on Genmab A/S (NASDAQ:GMAB) to $33 from $34. It maintained an “Equal Weight” rating on the shares. On May 7, Genmab A/S (NASDAQ:GMAB) reported revenue of $896 million for Q1 2026, […]
Junk-Rated Firms Rush to Reprice Risky Debt as Demand Surges
(Bloomberg) -- Junk-rated firms are rushing to reprice and refinance debt, seizing on renewed investor appetite for riskier US dollar-denominated loans to slash borrowing costs. Most Read from BloombergAmbani’s Cola War With Coke, Pepsi Spurs Fridge Bonanza in IndiaInside a Year of Chaos and Conflict at Kevin Hart’s Media CompanyIran Makes New Offer on Uranium in Response to US, WSJ SaysMamdani Scraps Property Tax Hike, Counts Second-Home RevenueMore than 20 companies have kicked off deals to cu
Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi‑Year Share Performance
Wondering whether Genmab stock still offers value at current levels, or if the best of the opportunity is already behind it, starts with understanding what the recent price moves really say about expectations. Over the last week the stock is up 4.1%, while the 1 year return sits at 36.3%. This is even though the year to date return is a 12.4% decline and the 3 and 5 year returns are 38.7% and 21.2% declines respectively. These mixed returns have kept attention on Genmab, with recent coverage...
Genmab A/S Q1 Earnings Call Highlights
Genmab A/S (NASDAQ:GMAB) reported first-quarter 2026 results highlighting revenue growth, expanding proprietary product sales, and continued investment in its late-stage pipeline, while maintaining profitability. President and CEO Jan van de Winkel said the company “continued to deliver strong finan
DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push
Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company continued investing heavily in its late-stage oncology pipeline.